Acute Deep Vein Thrombosis in the Setting of Tirzepatide Use: A Case Highlighting Emerging Concerns

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 agonist, is gaining popularity for its weight reduction, improved glycemic control, and cardiorenal benefits. While it is generally well tolerated, thrombotic events have not been commonly reported. We report a case of a woman who developed an unprovoked deep vein thrombosis within months of starting tirzepatide. An extensive hypercoagulability workup was negative. Her symptoms improved with anticoagulation and discontinuation of tirzepatide. This case highlights a potential risk of thromboembolic events associated with tirzepatide. Clinicians need to be vigilant and exercise extreme caution as the emerging adverse event profile of this novel medication unfolds.